Royalty Pharma (RPRX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1-year target prices for Royalty Pharma's stock. Their RPRX share price forecasts range from $48.00 to $60.00. On average, they expect the company's share price to reach $53.25 in the next year. This suggests a possible upside of 102.2% from the stock's current price.
View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts.

Royalty Pharma's stock was trading at $39.52 at the start of the year. Since then, RPRX stock has decreased by 33.4% and is now trading at $26.33.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our RPRX earnings forecast.

Royalty Pharma plc (NASDAQ:RPRX) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.02. The biopharmaceutical company earned $545 million during the quarter, compared to the consensus estimate of $538.52 million. Royalty Pharma had a net margin of 10.84% and a trailing twelve-month return on equity of 29.03%.

Royalty Pharma announced a quarterly dividend on Monday, July 17th. Stockholders of record on Friday, August 18th will be given a dividend of $0.20 per share on Friday, September 15th. This represents a $0.80 annualized dividend and a yield of 3.04%. The ex-dividend date is Thursday, August 17th.
Read our dividend analysis for RPRX.

ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED), Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (PILL), VictoryShares Free Cash Flow ETF (VFLO), VictoryShares Nasdaq Next 50 ETF (QQQN) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.80 per share and currently has a dividend yield of 3.04%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 186.05%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, RPRX will have a dividend payout ratio of 20.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

(RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

Royalty Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.42%), Baillie Gifford & Co. (3.05%), JPMorgan Chase & Co. (1.44%), State Street Corp (1.35%), Geode Capital Management LLC (1.01%) and abrdn plc (0.64%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Adage Capital Partners Gp, LL, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne.
View institutional ownership trends.

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RPRX stock can currently be purchased for approximately $26.33.

Royalty Pharma (NASDAQ:RPRX) has a market capitalization of $15.85 billion and generates $2.24 billion in revenue each year. The biopharmaceutical company earns $42.83 million in net income (profit) each year or $0.43 on an earnings per share basis.

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The official website for the company is www.royaltypharma.com. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at ir@royaltypharma.com.